Radiobiological evaluation of organs at risk for electronic high-dose-rate brachytherapy in uveal melanoma: a radiobiological modeling study
Year: 2021
Type: article
Abstract: Purpose: The objective of this study was to examine feasibility of single-or hypo-fraction of high-dose-rate (HDR) electronic brachytherapy (eBT) in uveal melanoma treatment.Material and methods: Biologically effective doses (BED) of organs at risk (OARs) were compared to those of iodine-125-based eye plaque low-dose-rate brachytherapy ( 125 I LDR-BT) with vitreous replacement (VR).Single-or hypo-fractionated equivalent physical doses (SFEDs or HFEDs) for tumor were calculated from tumor BED of 125 I LDR-BT using linear-quadratic (LQ) and universal survival curve (USC) models.BED OARs doses to retina opposite the implant, macula, optic disc, and lens were calculated and compared among SFED, HFED, and 125 I LDR-BT.Electronic BT of 50 kVp was considered assuming dose fall-off as clinically equivalent to 125 I LDR-BT.All OARs BEDs were analyzed with and without silicone oil VR.Results: For a single-fraction incorporating VR, the median/interquartile range of LQ (USC)-based BED doses of the retina opposite the implant, macula, optic disc, and lens were 16%/1.2%(33%/4%), 35%/19.5% (64%/17.7%),37%/19% (75%/17.8%),and 27%/7.9%(68%/23.2%) of those for 125 I LDR-BT, respectively.SFED tumor values were 29.8/0.2Gy and 51.7/0.5 Gy when using LQ and USC models, respectively, which could be delivered within 1 hour.SFED can be delivered within 1 hour using a high-dose-rate eBT.Even four-fraction delivery of HFED without VR resulted in higher OARs doses in the macula, optic disc, and lens (135 ~ 159%) than when using 125 I LDR-BT technique.A maximum p-value of 0.005 was observed for these distributions. Conclusions:The simulation of single-fraction eBT, including vitreous replacement, resulted in significantly reduced OARs doses (16 ~ 75%) of that achieved with 125 I LDR-BT.
Institution: University of Iowa
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $269
OpenAlex ID: W3208068255